Emergent BioSolutions, Inc.
2273 Research Boulevard
Suite 400
Rockville,
MD 20850
United States - Map
Phone: 301-795-1800
Fax: 301-795-1899
Web Site: http://www.emergentbiosolutions.com
| Emergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The companys earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency. The company was founded in 1998 and is based in Rockville, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Fuad El-Hibri , 51
Founder, Chairman and Chief Exec. Officer |
$
861.00K |
$
0 | Mr. Daniel J. Abdun-Nabi , 54
Pres, Chief Operating Officer |
$
602.00K |
$
0 | Mr. R. Don Elsey , 56
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. & Admin. and Treasurer |
$
414.00K |
$
632.00K | Dr. Stephen Lockhart , 52
Sr. VP of Product Devel. |
$
371.00K |
$
92.00K | Mr. Kyle W. Keese , 47
Sr. VP of Manufacturing Operations |
$
376.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
0.28 (2.00%) 
Profile
